The Tuesday email
It was 6:40 on a Tuesday in February 2024, and I was reading a bid tab on my phone in a parking garage. Two finalists for a fleet replacement: 240 infusion pumps, 60 syringe pumps, four ICUs. Roughly $1.4 million in capital — plus whatever the next five years decided to cost us.
The incumbent came in at $1,384,200. The challenger at $1,398,600. Fourteen thousand four hundred dollars apart, less than 1% of the contract. On paper that's a rounding error. In practice it was the entire decision.
My job is to review device contracts and supplier files before they reach our value analysis committee — roughly 300 packets a year across a three-hospital system. I rejected 17% of first submissions in 2024, mostly over spec sheets that didn't match the sample and sterilization certificates with the wrong lot ranges. Nobody thanks you for the rejections. They thank you when a recall letter lands and the traceability file is already built.
The reason we were running this bid at all: our two older ICUs still ran Medfusion 4000 pumps, and the service contract had been re-papered when ICU Medical completed its acquisition of Smiths Medical in January 2022 (Source: ICU Medical announcement, January 2022). Mostly smooth on the clinical side, mildly painful on the procurement side — new part numbers, new contract language, one very confusing freight invoice. But it forced the question. Replace now, or run the old fleet another five years?
We ran the bid. That's where the trouble started.
Two quotes, and a number I didn't trust
Here's the part of device procurement that doesn't make it into the glossy decks: the quote is a floor, not a price.
I learned that the slow way. It took me about three years and close to 400 vendor quotes to understand that the number on page one is almost never the number that leaves the bank account. Three years, four hundred quotes, and one budget variance in 2021 that I still hear about at Thanksgiving.
So on this bid I did what we now do on every capital purchase. I sent both finalists the same email, verbatim:
"Please provide a complete list of every fee that could appear on an invoice in years one through five — including optional line items, consumables escalation, training beyond go-live, integration work, freight, and out-of-warranty repair. If a fee exists, list it, even if you expect us not to incur it."
The incumbent sent two pages. The challenger sent eleven.
That asymmetry — not the $14,400 — is what made me start pulling the thread.
Page nine
The two-page fee schedule was accurate as far as it went. It just didn't go far.
- Clinical application training was "included" at go-live only. Ongoing annual competency training ran $9,800 a year, billed per educator day.
- The proprietary infusion sets carried an 8% premium over the comparable sets we'd been quoted separately — and the pumps were locked to them. On our volume that's roughly $31,000 a year.
- Service contract escalation was capped at 6% annually. The other quote capped at 3%. Over five years that's the difference between a fixed cost and a slow leak.
- Freight and installation across four sites: $14,400, listed as "TBD."
Five-year total for the lower quote: around $1,512,000. Five-year total for the higher quote, which listed every ugly number up front: around $1,431,000.
The cheaper bid was $81,000 more expensive. That's 5.8% — larger than the entire gap between the two quotes.
I have mixed feelings about this part of the job. On one hand, I want to believe a vendor who omits fees is being dishonest. On the other, I've sat close enough to the sales side to know most of these omissions aren't malice — they're plumbing. Capital reps quote capital, consumables reps quote consumables, service quotes service, and nobody owns the combined picture. The effect on the buyer is identical either way.
Where the money actually was
I expected the hidden costs to sit in the capital line. Big machine, big markup, right?
They weren't. Almost all of it was downstream — consumables, service, training. The capital number was honest. The operating number was the story.
That pattern has repeated every time since. Acquisition price is the most visible part of device cost and the least important one over a five-year horizon. A $1,400 pump that eats $340 a month in disposables is not a $1,400 pump. It's a $22,000 pump with a good marketing department.
Where else this hides
We folded three other categories into that quarter's audit, mostly because the same committee had to sign off on all of them and I wanted one honest picture instead of four flattering ones.
IV catheters. We standardize on two safety lines, and the Smiths Medical IV catheters — Jelco and Protectiv — sit in two of our four units. Same SKU, three distributors, a 19% spread between the high and low price in our 2023 audit. Nobody was lying. The distributors priced to whichever contract tier we happened to land in, and the tiers weren't comparable.
Ostomy supplies. About $190,000 a year system-wide. Roughly one in 500 Americans lives with an ostomy (United Ostomy Associations of America), so it's a small category with a long tail of SKUs — exactly where pricing gets opaque. The same pouch and barrier ring varied 22% between vendors. And the "free" dispensing and patient-support program we were offered carried a per-patient monthly management fee buried 30 pages into the service agreement. Free is a word, not a number.
Wound care. This is where non-clinical colleagues give me the blankest stares. What is wound care, exactly? Broadly, it's the clinical management of a break in skin integrity — surgical incisions, traumatic wounds, pressure injuries, diabetic foot ulcers, venous stasis ulcers — from a simple dressing change up through negative pressure therapy and skin substitutes. From a procurement standpoint it's the messiest category we buy: SKU sprawl, complicated reimbursement coding, and strong clinician preferences that are hard to argue with on price alone.
Cardiac stents. I mention this one only to make a point. We don't buy stents — that's a physician preference item running through a different channel entirely. But a drug-eluting stent can vary two- to three-fold in price between hospitals for the same device, and published analyses have been documenting that dispersion for years. If a category with roughly 600,000 to 1 million PCI procedures a year in the U.S. still shows that kind of spread, then transparency isn't a niche problem. It's structural.
What we changed
Three things. None of them clever.
- A one-page "total invoice reality" appendix is now mandatory on any capital device bid over $50,000. No appendix, no committee review. The first vendor who complained about it later told me it made their internal handoffs easier. Did not expect that.
- We ask "what's not included" before we ask "what's the price." The order matters more than I assumed. Ask about price first and the whole conversation anchors on the number everyone can already see.
- We score consumables lock-in as its own line item. If a pump only runs proprietary sets, that's a five-year commitment, and it gets priced like one.
What I'd tell the next person
That February bid changed how I think about the phrase "lowest responsible bidder." Responsible is the word doing all the work, and the only way to know whether a bid is responsible is to see the whole number.
Look — I'm not saying the higher quote is always the honest one. I've been burned by a "transparent" vendor who was transparent about the wrong things. What I'm saying is that the vendor who lists every fee up front, even when the total looks worse, hands you something the other one didn't: a number you can plan against.
Planning against a number is the entire job.
The incumbent's rep called me in April, after we'd awarded elsewhere, and asked what went wrong. I sent him the appendix. He called back two weeks later and said his team had never actually added up the five-year total before. That's the most honest answer I've gotten in eleven years of doing this.
Contract and pricing figures here come from internal 2024 bid documentation and are rounded; device pricing varies by contract, volume, and region, so verify current pricing against your own quotes. Acquisition details referenced from ICU Medical's January 2022 announcement. Ostomy prevalence figures from the United Ostomy Associations of America.